Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US10131907 | ALNYLAM PHARMS INC | Glycoconjugates of RNA interference agents |
Aug, 2028
(5 years from now) | |
US8828956 | ALNYLAM PHARMS INC | Carbohydrate conjugates as delivery agents for oligonucleotides |
Dec, 2028
(5 years from now) | |
US9370581 | ALNYLAM PHARMS INC | Carbohydrate conjugates as delivery agents for oligonucleotides |
Dec, 2028
(5 years from now) | |
US10806791 | ALNYLAM PHARMS INC | Carbohydrate conjugates as delivery agents for oligonucleotides |
Dec, 2028
(5 years from now) | |
US8106022 | ALNYLAM PHARMS INC | Carbohydrate conjugates as delivery agents for oligonucleotides |
Dec, 2029
(6 years from now) | |
US10570391 | ALNYLAM PHARMS INC | RNAi agents, compositions and methods of use thereof for treating transthyretin (TTR) associated diseases |
Nov, 2032
(9 years from now) | |
US9399775 | ALNYLAM PHARMS INC | RNAi agents, compositions and methods of use thereof for treating transthyretin (TTR) associated diseases |
Nov, 2032
(9 years from now) | |
US11401517 | ALNYLAM PHARMS INC | Modified double-stranded RNA agents |
Aug, 2035
(12 years from now) | |
US10612024 | ALNYLAM PHARMS INC | Modified double-stranded RNA agents |
Aug, 2035
(12 years from now) | |
US11286486 | ALNYLAM PHARMS INC | Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases |
Jul, 2036
(13 years from now) | |
US10683501 | ALNYLAM PHARMS INC | Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases |
Jul, 2036
(13 years from now) | |
US10208307 | ALNYLAM PHARMS INC | Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases |
Jul, 2036
(13 years from now) | |
CN102006890A | ALNYLAM PHARMS INC | Targeting Lipid |
Oct, 2015
(7 years ago) | |
EP3156077B1 | ALNYLAM PHARMS INC | Targeting Lipids |
Dec, 2028
(5 years from now) | |
EP2231195B1 | ALNYLAM PHARMS INC | Targeting Lipids |
Dec, 2028
(5 years from now) | |
EP2231194B1 | ALNYLAM PHARMS INC | Folate-Irna Conjugates |
Dec, 2028
(5 years from now) | |
EP2231195A2 | ALNYLAM PHARMS INC | Targeting Lipids |
Dec, 2028
(5 years from now) | |
EP3156077A1 | ALNYLAM PHARMS INC | Targeting Lipids |
Dec, 2028
(5 years from now) | |
EP2231194A2 | ALNYLAM PHARMS INC | Folate-Irna Conjugates |
Dec, 2028
(5 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Jun 13, 2027 |
Drugs and Companies using VUTRISIRAN ingredient
NCE-1 date: June, 2026
Market Authorisation Date: 13 June, 2022
Treatment: Amvuttra is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults
Dosage: SOLUTION;SUBCUTANEOUS
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US9539250 | MELINTA | Salt and crystalline forms thereof of a drug |
Oct, 2025
(2 years from now) | |
US8273892 | MELINTA | Salt and crystalline forms thereof of a drug |
Aug, 2026
(3 years from now) | |
US8871938 | MELINTA | Process for making quinolone compounds |
Sep, 2029
(6 years from now) | |
USRE46617 | MELINTA | Process for making quinolone compounds |
Dec, 2029
(6 years from now) | |
US7728143 | MELINTA | Salt and crystalline forms thereof of a drug |
Jun, 2031
(8 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8648093 | MELINTA | Salt and crystalline forms thereof of a drug |
Oct, 2025
(2 years from now) | |
US8969569 | MELINTA | Salt and crystalline forms thereof of a drug |
Oct, 2025
(2 years from now) | |
US8252813 | MELINTA | Salt and crystalline forms thereof of a drug |
Oct, 2026
(3 years from now) | |
US9750822 | MELINTA | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(6 years from now) | |
US8410077 | MELINTA | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(6 years from now) | |
US9200088 | MELINTA | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(6 years from now) | |
US7635773 | MELINTA | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(6 years from now) | |
US9493582 | MELINTA | Alkylated cyclodextrin compositions and processes for preparing and using the same |
Feb, 2033
(10 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Jun 19, 2022 |
New Indication (I) | Oct 24, 2022 |
Generating Antibiotic Incentives Now (GAIN) | Jun 19, 2027 |
Drugs and Companies using DELAFLOXACIN MEGLUMINE ingredient
NCE-1 date: June, 2026
Market Authorisation Date: 19 June, 2017
Treatment: Treatment of acute bacterial skin and skin structure infections caused by designated susceptible bacteria in adults
Dosage: POWDER;INTRAVENOUS
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US11499050 | PROVEPHARM SAS | NA |
Dec, 2037
(14 years from now) | |
US10927258 | PROVEPHARM SAS | Process for the preparation of Indigotindisulfonate sodium (indigo carmine) |
Dec, 2037
(14 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Jul 8, 2027 |
Drugs and Companies using INDIGOTINDISULFONATE SODIUM ingredient
NCE-1 date: July, 2026
Market Authorisation Date: 08 July, 2022
Treatment: NA
Dosage: SOLUTION;INTRAVENOUS
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US9181200 | BRISTOL | Pyrimidinedione compounds |
Jun, 2034
(11 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9585883 | BRISTOL | Pyrimidinedione compounds |
Jun, 2034
(11 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Apr 28, 2027 |
Drugs and Companies using MAVACAMTEN ingredient
NCE-1 date: April, 2026
Market Authorisation Date: 28 April, 2022
Treatment: Treatment of adults with symptomatic new york heart association (nyha) class ii-iii obstructive hypertrophic cardiomyopathy (hcm) to improve functional capacity and symptoms
Dosage: CAPSULE;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US9545405 | PFIZER | Pyrrolo[2,3-D]pyrimidine derivatives |
Feb, 2034
(11 years from now) | |
US9035074 | PFIZER | Pyrrolo[2,3-D]pyrimidine derivatives |
Feb, 2034
(11 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9549929 | PFIZER | Pyrrolo[2,3-D]pyrimidine derivatives |
Feb, 2034
(11 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Jan 14, 2027 |
Drugs and Companies using ABROCITINIB ingredient
NCE-1 date: January, 2026
Market Authorisation Date: 14 January, 2022
Treatment: Treatment of adults with refractory, moderate-to-severe atopic dermatitis not adequately controlled with other systemic drug products or when use of those therapies is inadvisable
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US6812238 | ASTELLAS | N-substituted carbamoyloxyalkyl-azolium derivatives |
Oct, 2025
(2 years from now) | |
US10812238 | ASTELLAS | Configurable reference signals |
Oct, 2025
(2 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10603280 | ASTELLAS | Active ingredient containing stabilised solid medicinal forms and methods for the production thereof |
Sep, 2027
(4 years from now) | |
US10206879 | ASTELLAS | Active ingredient containing stabilised solid forms and method for the production thereof |
Sep, 2027
(4 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Mar 6, 2022 |
New Chemical Entity Exclusivity (NCE) | Mar 6, 2020 |
Generating Antibiotic Incentives Now (GAIN) | Mar 6, 2027 |
Drugs and Companies using ISAVUCONAZONIUM SULFATE ingredient
NCE-1 date: March, 2026
Market Authorisation Date: 06 March, 2015
Treatment: NA
Dosage: POWDER;INTRAVENOUS
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US8114863 | GUERBET | Compounds comprising short aminoalcohol chains and metal complexes for medical imaging |
Sep, 2028
(5 years from now) | |
US10973934 | GUERBET | Gadolinium bearing PCTA-based contrast agents |
Aug, 2039
(16 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Sep 21, 2027 |
Drugs and Companies using GADOPICLENOL ingredient
NCE-1 date: September, 2026
Market Authorisation Date: 21 September, 2022
Treatment: NA
Dosage: SOLUTION;INTRAVENOUS
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US9108973 | TAIHO ONCOLOGY | 3,5-disubstituted alkynylbenzene compound and salt thereof |
Feb, 2033
(10 years from now) | |
US10434103 | TAIHO ONCOLOGY | Crystal of 3,5-disubstituted benzene alkynyl compound |
Mar, 2036
(13 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Sep 30, 2027 |
Drugs and Companies using FUTIBATINIB ingredient
NCE-1 date: September, 2026
Market Authorisation Date: 30 September, 2022
Treatment: Method of treating intrahepatic cholangiocarcinoma
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US9474780 | ELI LILLY AND CO | GIP and GLP-1 co-agonist compounds |
Jan, 2036
(12 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8734394 | ELI LILLY AND CO | Automatic injection device with delay mechanism including dual functioning biasing member |
Feb, 2031
(8 years from now) | |
US9402957 | ELI LILLY AND CO | Automatic injection device with delay mechanism including dual functioning biasing member |
Jun, 2031
(8 years from now) | |
US11357820 | ELI LILLY AND CO | GIP/GLP1 agonist compositions |
Jun, 2039
(16 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | May 13, 2027 |
Drugs and Companies using TIRZEPATIDE ingredient
NCE-1 date: May, 2026
Market Authorisation Date: 13 May, 2022
Treatment: Mounjaro is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
Dosage: SOLUTION;SUBCUTANEOUS
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US8648097 | SANTEN | Pyridylaminoacetic acid compound |
Oct, 2029
(6 years from now) | |
US10774072 | SANTEN | Crystal of N-substituted sulfonamide compound |
Jun, 2035
(12 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8685986 | SANTEN | Medical composition for treatment or prophylaxis of glaucoma |
Oct, 2029
(6 years from now) | |
US10702511 | SANTEN | Pharmaceutical formulations comprising a pyridylaminoacetic acid compound |
Jan, 2035
(11 years from now) | |
US10765750 | SANTEN | Pharmaceutical composition containing pyridylaminoacetic acid compound |
Jan, 2035
(11 years from now) | |
US10179127 | SANTEN | Pharmaceutical formulations comprising a pyridylaminoacetic acid compound |
Jan, 2035
(11 years from now) | |
US11197849 | SANTEN | Pharmaceutical formulations comprising a pyridylaminoacetic acid compound |
Jan, 2035
(11 years from now) | |
US9415038 | SANTEN | Pharmaceutical formulations comprising a pyridylaminoacetic acid compound |
Jan, 2035
(11 years from now) | |
USRE48183 | SANTEN | Pharmaceutical formulations comprising a pyridylaminoacetic acid compound |
Jan, 2035
(11 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Sep 22, 2027 |
Drugs and Companies using OMIDENEPAG ISOPROPYL ingredient
NCE-1 date: September, 2026
Market Authorisation Date: 22 September, 2022
Treatment: Method of treating open-angle glaucoma or ocular hypertension in patients
Dosage: SOLUTION;OPHTHALMIC
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US10406240 | AAA USA NOVARTIS | PSMA binding ligand-linker conjugates and methods for using |
Aug, 2028
(5 years from now) | |
US11318121 | AAA USA NOVARTIS | PSMA binding ligand-linker conjugates and methods for using |
Aug, 2028
(5 years from now) | |
US10398791 | AAA USA NOVARTIS | Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
Oct, 2034
(11 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Mar 23, 2027 |
Drugs and Companies using LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN ingredient
NCE-1 date: March, 2026
Market Authorisation Date: 23 March, 2022
Treatment: For treatment of adult patients with prostate-specific membrane antigen (psma)-positive metastatic castration-resistant prostate cancer (mcrpc) who have been treated with androgen receptor (ar) pathway inhibition and taxane-based chemotherapy
Dosage: SOLUTION;INTRAVENOUS
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US8785450 | AGIOS PHARMS INC | Therapeutic compounds and compositions |
Feb, 2031
(8 years from now) | |
US11254652 | AGIOS PHARMS INC | Crystalline forms of N-(4-(4-(cyclopropymethyl)piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide |
Nov, 2038
(15 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10632114 | AGIOS PHARMS INC | Pyruvate kinase activators for use in therapy |
May, 2032
(9 years from now) | |
US9682080 | AGIOS PHARMS INC | Pyruvate kinase activators for use in therapy |
May, 2032
(9 years from now) | |
US9980961 | AGIOS PHARMS INC | Pyruvate kinase activators for use in therapy |
May, 2032
(9 years from now) | |
US9193701 | AGIOS PHARMS INC | Pyruvate kinase activators for use in therapy |
Oct, 2032
(9 years from now) | |
US11234976 | AGIOS PHARMS INC | Methods of using pyruvate kinase activators |
Oct, 2038
(15 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Feb 17, 2027 |
Drugs and Companies using MITAPIVAT SULFATE ingredient
NCE-1 date: February, 2026
Market Authorisation Date: 17 February, 2022
Treatment: Method for increasing the lifetime of red blood cells (rbcs) for the treatment of hemolytic anemia in adults with pyruvate kinase (pk) deficiency; Method of using a pyruvate kinase activator for the treatment of hemolytic anemia in adults with pyruvate kinase (pk) deficiency; Method of using a pyruvate kinase activator for the treatment of hemolytic anemia in adults with pyruvate kinase (pk) deficiency by administering a daily dose of 10mg to 100mg
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US9732075 | IDORSIA | Benzimidazole-proline derivatives |
Jun, 2033
(10 years from now) | |
US9790208 | IDORSIA | Crystalline salt form of (S)-(2-(6-chloro-7-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonist |
Dec, 2034
(11 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10023560 | IDORSIA | Crystalline salt form of (S)-(2-(6 chloro-7-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonist |
Dec, 2034
(11 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Apr 7, 2027 |
Drugs and Companies using DARIDOREXANT HYDROCHLORIDE ingredient
NCE-1 date: April, 2026
Market Authorisation Date: 07 April, 2022
Treatment: Treatment of insomnia
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9872865 | AMYLYX | Compositions for improving cell viability and methods of use thereof |
Dec, 2033
(10 years from now) | |
US11071742 | AMYLYX | Compositions for improving cell viability and methods of use thereof |
Dec, 2033
(10 years from now) | |
US10251896 | AMYLYX | Compositions for improving cell viability and methods of use thereof |
Dec, 2033
(10 years from now) | |
US10857162 | AMYLYX | Compositions for improving cell viability and methods of use thereof |
Dec, 2033
(10 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Sep 29, 2027 |
Drugs and Companies using SODIUM PHENYLBUTYRATE; TAURURSODIOL ingredient
NCE-1 date: September, 2026
Market Authorisation Date: 29 September, 2022
Treatment: Treatment of amyotrophic lateral sclerosis (als) in adults
Dosage: FOR SUSPENSION;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10849884 | LUPIN | Secnidazole for use in the treatment of bacterial vaginosis |
Sep, 2035
(12 years from now) | |
US11324721 | LUPIN | Secnidazole for use in the treatment of trichomoniasis |
Sep, 2035
(12 years from now) | |
US10857133 | LUPIN | Secnidazole for use in the treatment of bacterial vaginosis |
Sep, 2035
(12 years from now) | |
US10682338 | LUPIN | Secnidazole for use in the treatment of bacterial vaginosis |
Sep, 2035
(12 years from now) | |
US11000508 | LUPIN | Secnidazole for use in the treatment of trichomoniasis |
Sep, 2035
(12 years from now) | |
US11020377 | LUPIN | Secnidazole for use in the treatment of bacterial vaginosis |
Sep, 2035
(12 years from now) | |
US11000507 | LUPIN | Secnidazole for use in the treatment of bacterial vaginosis |
Sep, 2035
(12 years from now) | |
US10335390 | LUPIN | Secnidazole for use in the treatment of bacterial vaginosis |
Sep, 2035
(12 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Sep 15, 2022 |
New Indication (I) | Jun 30, 2024 |
New Patient Population (NPP) | Jan 26, 2025 |
Generating Antibiotic Incentives Now (GAIN) | Sep 15, 2027 |
Drugs and Companies using SECNIDAZOLE ingredient
NCE-1 date: September, 2026
Market Authorisation Date: 15 September, 2017
Treatment: Treatment of bacterial vaginosis in female patients 12 years of age and older; Treatment of trichomoniasis in patients 12 years of age and older; Treatment of trichomoniasis in adults; Treatment of bacterial vaginosis in adult women
Dosage: GRANULE;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
USRE47929 | BRISTOL | Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFNα responses |
Nov, 2033
(10 years from now) | |
US10000480 | BRISTOL | Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses |
Nov, 2033
(10 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11021475 | BRISTOL | Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses |
Nov, 2033
(10 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Sep 9, 2027 |
Drugs and Companies using DEUCRAVACITINIB ingredient
NCE-1 date: September, 2026
Market Authorisation Date: 09 September, 2022
Treatment: Treatment of moderate-to-severe plaque psoriasis in adults who are canididates for systemic therapy or phototherapy
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US8680136 | REMPEX | Cyclic boronic acid ester derivatives and therapeutic uses thereof |
Aug, 2031
(8 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11007206 | REMPEX | Cyclic boronic acid ester derivatives and therapeutic uses thereof |
Aug, 2031
(8 years from now) | |
US9694025 | REMPEX | Cyclic boronic acid ester derivatives and therapeutic uses thereof |
Aug, 2031
(8 years from now) | |
US10183034 | REMPEX | Therapeutic uses of pharmaceutical compositions comprising cyclic boronic acid ester derivatives |
Aug, 2031
(8 years from now) | |
US10172874 | REMPEX | Pharmaceutical compositions comprising cyclic boronic acid ester derivatives |
Aug, 2031
(8 years from now) | |
US10561675 | REMPEX | Cyclic boronic acid ester derivatives and therapeutic uses thereof |
Aug, 2031
(8 years from now) | |
US11376237 | REMPEX | Methods of treating bacterial infections |
Apr, 2039
(16 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Aug 29, 2022 |
Generating Antibiotic Incentives Now (GAIN) | Aug 29, 2027 |
Drugs and Companies using MEROPENEM; VABORBACTAM ingredient
NCE-1 date: August, 2026
Market Authorisation Date: 29 August, 2017
Treatment: Treatment of complicated urinary tract infections (cuti) including pyelonephritis caused by the following susceptible microorganisms: escherichia coli, klebsiella pneumonia, enterobacter cloacae species complex with meropenem & vaborbactam as specified; Treatment of patients 18 years of age and older with complicated urinary tract infections caused by susceptible microorganisms; Treatment of complicated urinary tract infection (cuti) including pyelonephritis caused by the following susceptible microorganisms: escherichia coli, klebsiella pneumonia, and enterobacter cloacae species complex; Treatment of complicated urinary tract infections (cuti) including pyelonephritis caused by the following susceptible microorganisms: escherichia coli,klebsiella pneumonia,enterobacter cloacae species complex with meropenem & vaborbactam as specified
Dosage: POWDER;INTRAVENOUS
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US8153632 | CTI BIOPHARMA CORP | Oxygen linked pyrimidine derivatives |
Jan, 2029
(5 years from now) | |
US8980873 | CTI BIOPHARMA CORP | 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene citrate salt |
Mar, 2030
(7 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9573964 | CTI BIOPHARMA CORP | Oxygen linked pyrimidine derivatives |
May, 2028
(5 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Feb 28, 2027 |
Drugs and Companies using PACRITINIB CITRATE ingredient
NCE-1 date: February, 2026
Market Authorisation Date: 28 February, 2022
Treatment: Use of pacritinib for inhibiting janus associated kinase 2(jak2); Treatment of myelofibrosis with pacritinib
Dosage: CAPSULE;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US10647649 | DERMAVANT SCI | Process for preparing tapinarof |
Nov, 2038
(15 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11458108 | DERMAVANT SCI | NA |
May, 2036
(13 years from now) | |
US10195160 | DERMAVANT SCI | Topical pharmaceutical compositions |
May, 2036
(13 years from now) | |
US10426743 | DERMAVANT SCI | Topical pharmaceutical compositions |
May, 2036
(13 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | May 23, 2027 |
Drugs and Companies using TAPINAROF ingredient
NCE-1 date: May, 2026
Market Authorisation Date: 23 May, 2022
Treatment: Topical treatment of plaque psoriasis in adults
Dosage: CREAM;TOPICAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7858609 | MARINUS | Solid ganaxolone formulations and methods for the making and use thereof |
Nov, 2026
(3 years from now) | |
US8022054 | MARINUS | Liquid ganaxolone formulations and methods for the making and use thereof |
Nov, 2026
(3 years from now) | |
US8318714 | MARINUS | Liquid ganaxolone formulations and methods for the making and use thereof |
Nov, 2026
(3 years from now) | |
US8618087 | MARINUS | Solid ganaxolone formulations and methods for the making and use thereof |
Nov, 2026
(3 years from now) | |
US9056116 | MARINUS | Liquid ganaxolone formulations and methods for the making and use thereof |
Nov, 2026
(3 years from now) | |
US8367651 | MARINUS | Solid ganaxolone formulations and methods for the making and use thereof |
Nov, 2026
(3 years from now) | |
US9029355 | MARINUS | Solid ganaxolone compositions and methods for the making and use thereof |
Nov, 2026
(3 years from now) | |
US10603308 | MARINUS | Methods and compositions for treatment of epileptic disorders |
Aug, 2037
(14 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Jun 1, 2027 |
Drugs and Companies using GANAXOLONE ingredient
NCE-1 date: June, 2026
Market Authorisation Date: 01 June, 2022
Treatment: Treatment of seizures associated with cyclin-dependent kinase-like 5 (cdkl5) deficiency disorder (cdd) in patients 2 years of age and older
Dosage: SUSPENSION;ORAL
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic